Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Intercept Appoints Juan Carlos Lopez-Talavera SVP Medical Affairs | Contract Pharma

What are you searching for?

Sign in
Breaking News, Promotions & Moves

Intercept Appoints Juan Carlos Lopez-Talavera SVP Medical Affairs

Most recently served as head of hepatology R&D and vice president of medical affairs at Abbvie

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Intercept Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic underserved liver diseases, such as primary biliary cirrhosis (PBC) and nonalcoholic steatohepatitis (NASH), has named Juan Carlos Lopez-Talavera as senior vice president of medical affairs.

“Juan Carlos brings more than 20 years of industry and academic experience to Intercept and is a globally recognized hepatologist,” said David Shapiro, chief medical officer. “We will benefit greatly from Juan Carlos’s considerable expertise in working with the medical community to enhance understanding of underserved liver diseases and strategies for improving patient care.”

Dr. Lopez-Talavera most recently served as head of hepatology R&D and vice president of medical affairs at Abbvie, where he was responsible for all medical affairs activities supporting the global launch of Abbvie’s regimen for the treatment of Hepatitis C.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics